Francesca Giunchi
Overview
Explore the profile of Francesca Giunchi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
110
Citations
1046
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
de Barros H, Downes M, Droghetti M, Bekers E, Giunchi F, Brunocilla E, et al.
Urology
. 2025 Feb;
PMID: 39922236
Objective: To evaluate the occurrence and the oncological predictive value of cribriform growth and/or intraductal carcinoma (CR/IDC) in patients with ISUP grade group (GG) 2 prostate cancer (PCa) at radical...
2.
Angelicola S, Giunchi F, Ruzzi F, Frascino M, Pitzalis M, Scalambra L, et al.
J Transl Med
. 2025 Jan;
23(1):2.
PMID: 39748404
Background: Non-Small Cell Lung Cancer (NSCLC) is the leading cause of cancer death worldwide. Although immune checkpoint inhibitors (ICIs) have shown remarkable clinical efficacy, they can also induce a paradoxical...
3.
Di Federico A, Angelicola S, Frascino M, Siracusa I, Bisanti B, Ruzzi F, et al.
JCO Precis Oncol
. 2024 Dec;
8:e2400240.
PMID: 39637338
Purpose: Patients with tumors harboring class 3 mutations lack targeted therapies. These mutations are characterized by low/absent BRAF kinase domain activation and are believed to amplify already active RAS signaling,...
4.
Zanoni L, Fortunati E, Cuzzani G, Malizia C, Lodi F, Cabitza V, et al.
Pharmaceuticals (Basel)
. 2024 Nov;
17(11).
PMID: 39598380
Background/objectives: To evaluate T&N-staging diagnostic performance of [68Ga]Ga-FAPI-46 PET/CT (FAPI) in a suspected/confirmed lung cancer surgical cohort. Methods: Patients were enrolled in a prospective monocentric trial (EudraCT: 2021-006570-23) to perform...
5.
Boufaied N, Chetta P, Hallal T, Cacciatore S, Lalli D, Luthold C, et al.
Cancer Res
. 2024 Jun;
84(11):1834-1855.
PMID: 38831751
Significance: Lactate accumulation driven by high-fat diet and MYC reprograms the tumor microenvironment and promotes prostate cancer progression, supporting the potential of lactate as a biomarker and therapeutic target in...
6.
Droghetti M, Bianchi L, Presutti M, Vetrone L, Farolfi A, Mei R, et al.
Front Oncol
. 2024 May;
14:1324631.
PMID: 38807770
Introduction: Prostate-specific membrane antigen (PSMA) is a transmembrane protein expressed by normal prostatic tissue. Therefore, molecular imaging targeting PSMA (PSMA-PET) has gained particular interest and diffusion for PCa staging and...
7.
Cuzzani G, Fortunati E, Zanoni L, Nanni C, Antonacci F, Giunchi F, et al.
J Nucl Med
. 2024 Mar;
65(7):1161.
PMID: 38453360
No abstract available.
8.
Rosellini M, Mollica V, Marchetti A, Coluccelli S, Giunchi F, Tassinari E, et al.
Pathol Res Pract
. 2024 Jan;
254:155142.
PMID: 38277752
Background: Identifying biomarkers for metastatic renal cell carcinoma (mRCC) is an unmet need in actual immunotherapy era. Available data regarding chromosome 3p genes (i.e., VHL, PBRM1, SETD2) mutations as potential...
9.
Mollica V, Tassinari E, Santoni M, Marchese P, Giunchi F, Maloberti T, et al.
Pathol Res Pract
. 2023 Dec;
253:155008.
PMID: 38103361
Background: TERT promoter mutation is one of the most common genomic alterations in urothelial carcinoma (UC). Its prognostic role on patients' outcomes is still not clear. Methods: We performed a...
10.
Destefanis N, Fiano V, Milani L, Vasapolli P, Fiorentino M, Giunchi F, et al.
Front Oncol
. 2023 Oct;
13:1242639.
PMID: 37869094
Introduction: Prostate cancer (PCa) is the most frequent tumor among men in Europe and has both indolent and aggressive forms. There are several treatment options, the choice of which depends...